Investment
Features
FeesSafety
Academy
More
Pluang+

Compare YieldMax AMD Option Income Strategy ETF (AMDY) vs Novavax Inc (NVAX) Price & Performance

YieldMax AMD Option Income Strategy ETFTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

YieldMax AMD Option Income Strategy ETF vs Novavax Inc — how do they compare? YieldMax AMD Option Income Strategy ETF trades at $45.91, while Novavax Inc trades at $7.94 (market cap $1.31B). The key difference: YieldMax AMD Option Income Strategy ETF is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.

AMDYNVAX
Sector
Income / Options OverlayHealth
52-Week High
$59.52$11.19
52-Week Low
$29.80$6.22
Market Cap
$1.31B
Enterprise Value
$889.30M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

YieldMax AMD Option Income Strategy ETF

No Aura AI signal available yet.

Novavax Inc

Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.

The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About YieldMax AMD Option Income Strategy ETF

AMDY is an active ETF that seeks to generate weekly income by selling call options on AMD stock. It aims to provide investors with high yield while maintaining exposure to the price movements of Advanced Micro Devices.

Read more on AMDY

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX